Trial Profile
CS-8958 Phase 3 study in Pediatric Patients < 10 years of age - A open-labeled study of nebulized CS-8958 in the treatment of influenza virus infection -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 13 Sep 2017 Status changed from not yet recruiting to completed.
- 10 Oct 2016 New trial record